Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

Milind Javle,Sameek Roychowdhury,Robin Kate Kelley,Saeed Sadeghi,Teresa Macarulla,Dirk Waldschmidt,Lipika Goyal,Ivan Borbath,Anthony B. El-Khoueiry,Wei Peng Yong,Philip A. Philip,Michael Bitzer,Suebpong Tanasanvimon,Ai Li,Amit Pande,Stacie Peacock Shepherd,Susan Moran,Ghassan K. Abou-Alfa

Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.

2021

Milind Javle
Sameek Roychowdhury
Robin Kate Kelley
Saeed Sadeghi
Teresa Macarulla
Dirk Waldschmidt
Lipika Goyal
Ivan Borbath
Anthony B. El-Khoueiry
Wei Peng Yong
Philip A. Philip
Michael Bitzer
Suebpong Tanasanvimon
Ai Li
Amit Pande
Stacie Peacock Shepherd
Susan Moran
Ghassan K. Abou-Alfa

265Background: Treatment options for cholangiocarcinoma (CCA) after progression on first-line gemcitabine-based therapy are limited. Fibroblast growth factor receptor 2 (FGFR2) gene fusions occur i...

Keywords:

Medicine
Tyrosine-kinase inhibitor
Fibroblast growth factor receptor 2
Phases of clinical research
Gene
Cancer research
Fibroblast growth factor receptor
in patient
Gemcitabine
Fusion gene

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations